3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Leukemia
5
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Accelerated Phase
4
Blast Crisis
4
Neoplasms
3
Leukemia, Myeloid, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Gastrointestinal Stromal Tumors
2
Gastrointestinal Neoplasms
2
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Philadelphia Chromosome
1
Neoplasms by Histologic Type
1
Myeloproliferative Disorders
1
Malignant Hepatobiliary Neoplasm
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Glioblastoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Medullary
1
Carcinoma
1
Burkitt Lymphoma
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Interventions
Cyclophosphamide
53
fludarabine phosphate
50
Tacrolimus
41
Busulfan
41
Peripheral Blood Stem Cell Transplantation
37
Mycophenolic Acid
36
Whole-Body Irradiation
34
Antilymphocyte Serum
34
Cyclosporine
27
Methotrexate
25
fludarabine
24
Melphalan
20
Radiotherapy
19
Filgrastim
16
Methylprednisolone
14
Cord Blood Stem Cell Transplantation
12
Cytarabine
11
thymoglobulin
10
ruxolitinib
10
Specimen Handling
10
Biopsy
10
Cyclosporins
9
sargramostim
8
Sirolimus
8
Etoposide
8
Alemtuzumab
8
Thiotepa
7
Stem Cell Transplantation
7
Granulocyte Colony-Stimulating Factor
7
Azacitidine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Myeloproliferative Disorders
×
ponatinib
×
Clear all
NCT02467270
2026-03-17
OPTIC
Takeda
Phase 2
Completed
283 enrolled
31 charts